- Home
- NRIM vs VNDA Comparison
NRIM vs VNDA Comparison
Compare NRIM & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- VNDA
- Stock Information
- Founded
- NRIM 1990
- VNDA 2002
- Country
- NRIM United States
- VNDA United States
- Employees
- NRIM N/A
- VNDA N/A
- Industry
- NRIM Savings Institutions
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NRIM Finance
- VNDA Health Care
- Exchange
- NRIM Nasdaq
- VNDA Nasdaq
- Market Cap
- NRIM 514.9M
- VNDA 288.2M
- IPO Year
- NRIM N/A
- VNDA 2006
- Fundamental
- Price
- NRIM $96.46
- VNDA $4.97
- Analyst Decision
- NRIM
- VNDA Strong Buy
- Analyst Count
- NRIM 0
- VNDA 3
- Target Price
- NRIM N/A
- VNDA $15.33
- AVG Volume (30 Days)
- NRIM 73.5K
- VNDA 448.0K
- Earning Date
- NRIM 07-23-2025
- VNDA 07-30-2025
- Dividend Yield
- NRIM 2.65%
- VNDA N/A
- EPS Growth
- NRIM 46.48
- VNDA N/A
- EPS
- NRIM 7.52
- VNDA N/A
- Revenue
- NRIM $164,695,000.00
- VNDA $201,351,000.00
- Revenue This Year
- NRIM N/A
- VNDA $16.86
- Revenue Next Year
- NRIM $7.05
- VNDA $39.78
- P/E Ratio
- NRIM $12.84
- VNDA N/A
- Revenue Growth
- NRIM 26.35
- VNDA 13.37
- 52 Week Low
- NRIM $58.49
- VNDA $3.81
- 52 Week High
- NRIM $100.21
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- NRIM 56.53
- VNDA 59.81
- Support Level
- NRIM $96.01
- VNDA $4.85
- Resistance Level
- NRIM $100.21
- VNDA $5.12
- Average True Range (ATR)
- NRIM 2.39
- VNDA 0.20
- MACD
- NRIM 0.07
- VNDA 0.01
- Stochastic Oscillator
- NRIM 61.16
- VNDA 79.73
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.